Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis (EPIC-BioLINCC)

Other (4)

• CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body (phv00560098.v1.p1)
• NEWEPIC - Subject ID (phv00560097.v1.p1)
• NEWEPIC - Subject ID (phv00560099.v1.p1)
• SAMPLE_ID - Sample ID (phv00560100.v1.p1)